TWI450900B - 橋聯雜環化合物及使用方法 - Google Patents

Info

Publication number

TWI450900B

TWI450900B TW098109566A TW98109566A TWI450900B TW I450900 B TWI450900 B TW I450900B TW 098109566 A TW098109566 A TW 098109566A TW 98109566 A TW98109566 A TW 98109566A TW I450900 B TWI450900 B TW I450900B

Authority

TW

Taiwan

Prior art keywords

substituted

unsubstituted

group

alkyl

alkoxy

Prior art date

2008-03-24

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title description 150
• 150000002391 heterocyclic compounds Chemical class 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims description 517
• -1 perhaloalkyl Chemical group 0.000 claims description 346
• 125000000217 alkyl group Chemical group 0.000 claims description 238
• 125000000623 heterocyclic group Chemical group 0.000 claims description 170
• 125000003118 aryl group Chemical group 0.000 claims description 157
• 125000003545 alkoxy group Chemical group 0.000 claims description 146
• 125000001072 heteroaryl group Chemical group 0.000 claims description 132
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 128
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 111
• 125000000753 cycloalkyl group Chemical class 0.000 claims description 87
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 84
• 125000003277 amino group Chemical group 0.000 claims description 80
• 150000001412 amines Chemical class 0.000 claims description 75
• 125000003396 thiol group Chemical group [H]S* 0.000 claims description 75
• 125000005102 carbonylalkoxy group Chemical group 0.000 claims description 67
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 66
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 62
• 102000005962 receptors Human genes 0.000 claims description 59
• 108020003175 receptors Proteins 0.000 claims description 59
• 125000004104 aryloxy group Chemical group 0.000 claims description 58
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 56
• 208000010877 cognitive disease Diseases 0.000 claims description 55
• 150000003839 salts Chemical class 0.000 claims description 55
• 229910052799 carbon Inorganic materials 0.000 claims description 54
• 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 53
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 49
• 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 48
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 48
• 208000028017 Psychotic disease Diseases 0.000 claims description 41
• 102000015554 Dopamine receptor Human genes 0.000 claims description 40
• 108050004812 Dopamine receptor Proteins 0.000 claims description 40
• 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims description 39
• 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims description 39
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 39
• 125000006612 decyloxy group Chemical group 0.000 claims description 39
• 239000002858 neurotransmitter agent Substances 0.000 claims description 39
• 102000000543 Histamine Receptors Human genes 0.000 claims description 38
• 108010002059 Histamine Receptors Proteins 0.000 claims description 38
• 108060003345 Adrenergic Receptor Proteins 0.000 claims description 37
• 102000017910 Adrenergic receptor Human genes 0.000 claims description 37
• 230000001537 neural effect Effects 0.000 claims description 36
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 35
• 230000001404 mediated effect Effects 0.000 claims description 35
• RSPCKAHMRANGJZ-UHFFFAOYSA-N thiohydroxylamine Chemical group SN RSPCKAHMRANGJZ-UHFFFAOYSA-N 0.000 claims description 34
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
• 238000011282 treatment Methods 0.000 claims description 31
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 30
• 229910052757 nitrogen Inorganic materials 0.000 claims description 30
• 125000003107 substituted aryl group Chemical group 0.000 claims description 29
• 125000000304 alkynyl group Chemical group 0.000 claims description 26
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 26
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 25
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 22
• 125000004076 pyridyl group Chemical group 0.000 claims description 21
• 125000005121 aminocarbonylalkoxy group Chemical group 0.000 claims description 20
• 229910052739 hydrogen Inorganic materials 0.000 claims description 19
• 125000003342 alkenyl group Chemical group 0.000 claims description 17
• 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 17
• 125000004432 carbon atom Chemical group C* 0.000 claims description 16
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 15
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 13
• 239000003814 drug Substances 0.000 claims description 13
• 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 13
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 12
• 125000002252 acyl group Chemical group 0.000 claims description 12
• 150000001721 carbon Chemical group 0.000 claims description 10
• 229910000037 hydrogen sulfide Inorganic materials 0.000 claims description 10
• 239000008194 pharmaceutical composition Substances 0.000 claims description 10
• 125000006598 aminocarbonylamino group Chemical group 0.000 claims description 9
• KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 8
• 239000003937 drug carrier Substances 0.000 claims description 8
• 238000004519 manufacturing process Methods 0.000 claims description 8
• 229910052707 ruthenium Inorganic materials 0.000 claims description 8
• 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 claims description 7
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 7
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 6
• 150000008052 alkyl sulfonates Chemical class 0.000 claims description 4
• 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 3
• 125000001475 halogen functional group Chemical group 0.000 claims 20
• NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims 2
• DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 claims 2
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 128
• 125000005843 halogen group Chemical group 0.000 description 116
• 238000007429 general method Methods 0.000 description 89
• 230000027455 binding Effects 0.000 description 82
• 239000003446 ligand Substances 0.000 description 61
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
• 235000019439 ethyl acetate Nutrition 0.000 description 60
• 208000035475 disorder Diseases 0.000 description 54
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 52
• 201000010099 disease Diseases 0.000 description 52
• 238000002360 preparation method Methods 0.000 description 49
• 239000011541 reaction mixture Substances 0.000 description 44
• 230000000694 effects Effects 0.000 description 43
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
• 230000015572 biosynthetic process Effects 0.000 description 40
• 229940075993 receptor modulator Drugs 0.000 description 40
• 230000014511 neuron projection development Effects 0.000 description 39
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 39
• 239000000203 mixture Substances 0.000 description 36
• 208000024891 symptom Diseases 0.000 description 35
• 238000003556 assay Methods 0.000 description 34
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 34
• QQXLDOJGLXJCSE-KNVOCYPGSA-N tropinone Chemical compound C1C(=O)C[C@H]2CC[C@@H]1N2C QQXLDOJGLXJCSE-KNVOCYPGSA-N 0.000 description 34
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 32
• 238000004128 high performance liquid chromatography Methods 0.000 description 31
• 230000002829 reductive effect Effects 0.000 description 28
• 238000007363 ring formation reaction Methods 0.000 description 27
• 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 26
• 150000002148 esters Chemical class 0.000 description 26
• 239000000047 product Substances 0.000 description 26
• 201000000980 schizophrenia Diseases 0.000 description 26
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
• XXNOGQJZAOXWAQ-UHFFFAOYSA-N 4-chlorophenylhydrazine Chemical compound NNC1=CC=C(Cl)C=C1 XXNOGQJZAOXWAQ-UHFFFAOYSA-N 0.000 description 25
• 102100040368 5-hydroxytryptamine receptor 6 Human genes 0.000 description 25
• 210000002569 neuron Anatomy 0.000 description 25
• 230000008569 process Effects 0.000 description 25
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
• 230000007062 hydrolysis Effects 0.000 description 24
• 238000006460 hydrolysis reaction Methods 0.000 description 24
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
• 101710150235 5-hydroxytryptamine receptor 6 Proteins 0.000 description 21
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 21
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 21
• 230000009286 beneficial effect Effects 0.000 description 21
• 230000004064 dysfunction Effects 0.000 description 21
• 125000000547 substituted alkyl group Chemical group 0.000 description 20
• 238000011161 development Methods 0.000 description 19
• 230000018109 developmental process Effects 0.000 description 19
• 238000002347 injection Methods 0.000 description 19
• 239000007924 injection Substances 0.000 description 19
• 230000015654 memory Effects 0.000 description 18
• 230000007074 memory dysfunction Effects 0.000 description 18
• 239000012044 organic layer Substances 0.000 description 18
• 238000003786 synthesis reaction Methods 0.000 description 18
• 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 17
• 208000024827 Alzheimer disease Diseases 0.000 description 17
• QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 17
• 230000000875 corresponding effect Effects 0.000 description 17
• 229940076279 serotonin Drugs 0.000 description 17
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 16
• 230000003920 cognitive function Effects 0.000 description 16
• 208000027061 mild cognitive impairment Diseases 0.000 description 16
• 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 15
• 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 15
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
• 239000000243 solution Substances 0.000 description 15
• 102100039126 5-hydroxytryptamine receptor 7 Human genes 0.000 description 14
• 101710150237 5-hydroxytryptamine receptor 7 Proteins 0.000 description 14
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
• 210000004556 brain Anatomy 0.000 description 14
• 238000006243 chemical reaction Methods 0.000 description 14
• 230000001713 cholinergic effect Effects 0.000 description 14
• 239000012453 solvate Substances 0.000 description 14
• 239000002904 solvent Substances 0.000 description 14
• 230000003042 antagnostic effect Effects 0.000 description 13
• 230000001270 agonistic effect Effects 0.000 description 12
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 12
• 125000001309 chloro group Chemical group Cl* 0.000 description 12
• 230000002708 enhancing effect Effects 0.000 description 12
• 229920006395 saturated elastomer Polymers 0.000 description 12
• 208000020431 spinal cord injury Diseases 0.000 description 12
• 125000004149 thio group Chemical class *S* 0.000 description 12
• VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 11
• 208000018737 Parkinson disease Diseases 0.000 description 11
• 230000006378 damage Effects 0.000 description 11
• OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 11
• 230000000508 neurotrophic effect Effects 0.000 description 11
• 125000006574 non-aromatic ring group Chemical group 0.000 description 11
• 208000011580 syndromic disease Diseases 0.000 description 11
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
• RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 10
• 239000012043 crude product Substances 0.000 description 10
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 10
• 206010027175 memory impairment Diseases 0.000 description 10
• 210000005036 nerve Anatomy 0.000 description 10
• 230000004766 neurogenesis Effects 0.000 description 10
• 108090000623 proteins and genes Proteins 0.000 description 10
• 108091005435 5-HT6 receptors Proteins 0.000 description 9
• 241000282414 Homo sapiens Species 0.000 description 9
• 208000023105 Huntington disease Diseases 0.000 description 9
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
• 208000030886 Traumatic Brain injury Diseases 0.000 description 9
• 230000002159 abnormal effect Effects 0.000 description 9
• 239000002585 base Substances 0.000 description 9
• 238000004587 chromatography analysis Methods 0.000 description 9
• OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 9
• 208000014674 injury Diseases 0.000 description 9
• 210000002161 motor neuron Anatomy 0.000 description 9
• 230000004770 neurodegeneration Effects 0.000 description 9
• 208000015122 neurodegenerative disease Diseases 0.000 description 9
• 235000019260 propionic acid Nutrition 0.000 description 9
• 230000004936 stimulating effect Effects 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• 125000001424 substituent group Chemical group 0.000 description 9
• 125000004426 substituted alkynyl group Chemical group 0.000 description 9
• 210000000225 synapse Anatomy 0.000 description 9
• 230000009529 traumatic brain injury Effects 0.000 description 9
• 102100032509 Histamine H1 receptor Human genes 0.000 description 8
• 101001016841 Homo sapiens Histamine H1 receptor Proteins 0.000 description 8
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 8
• 208000002193 Pain Diseases 0.000 description 8
• 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 8
• 238000002648 combination therapy Methods 0.000 description 8
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 8
• 229940079593 drug Drugs 0.000 description 8
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 8
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 8
• 230000002401 inhibitory effect Effects 0.000 description 8
• 208000002780 macular degeneration Diseases 0.000 description 8
• 230000014759 maintenance of location Effects 0.000 description 8
• 230000035772 mutation Effects 0.000 description 8
• DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 8
• 125000004433 nitrogen atom Chemical group N* 0.000 description 8
• 150000002923 oximes Chemical class 0.000 description 8
• 230000008447 perception Effects 0.000 description 8
• 125000003373 pyrazinyl group Chemical group 0.000 description 8
• 229910052938 sodium sulfate Inorganic materials 0.000 description 8
• 235000011152 sodium sulphate Nutrition 0.000 description 8
• 125000005017 substituted alkenyl group Chemical group 0.000 description 8
• 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 8
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 8
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
• 206010003805 Autism Diseases 0.000 description 7
• 208000020706 Autistic disease Diseases 0.000 description 7
• 241000282465 Canis Species 0.000 description 7
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 7
• 208000006011 Stroke Diseases 0.000 description 7
• 230000032683 aging Effects 0.000 description 7
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 125000005589 carbonylalkylenealkoxy group Chemical group 0.000 description 7
• 210000003169 central nervous system Anatomy 0.000 description 7
• 230000034994 death Effects 0.000 description 7
• 231100000517 death Toxicity 0.000 description 7
• WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 7
• 125000001153 fluoro group Chemical group F* 0.000 description 7
• 201000006417 multiple sclerosis Diseases 0.000 description 7
• 230000016273 neuron death Effects 0.000 description 7
• 230000007935 neutral effect Effects 0.000 description 7
• 208000033808 peripheral neuropathy Diseases 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 125000004193 piperazinyl group Chemical group 0.000 description 7
• 230000003414 procognitive effect Effects 0.000 description 7
• 230000000750 progressive effect Effects 0.000 description 7
• 125000005415 substituted alkoxy group Chemical group 0.000 description 7
• 230000002194 synthesizing effect Effects 0.000 description 7
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• 125000004001 thioalkyl group Chemical group 0.000 description 7
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 7
• 108091005436 5-HT7 receptors Proteins 0.000 description 6
• 108010010803 Gelatin Proteins 0.000 description 6
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
• 208000026935 allergic disease Diseases 0.000 description 6
• 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 6
• 230000000561 anti-psychotic effect Effects 0.000 description 6
• 125000002837 carbocyclic group Chemical group 0.000 description 6
• 210000004027 cell Anatomy 0.000 description 6
• 230000001149 cognitive effect Effects 0.000 description 6
• 125000004122 cyclic group Chemical group 0.000 description 6
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
• 230000001747 exhibiting effect Effects 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• 239000008273 gelatin Substances 0.000 description 6
• 229920000159 gelatin Polymers 0.000 description 6
• 235000019322 gelatine Nutrition 0.000 description 6
• 235000011852 gelatine desserts Nutrition 0.000 description 6
• 150000002430 hydrocarbons Chemical group 0.000 description 6
• 210000003205 muscle Anatomy 0.000 description 6
• 210000001087 myotubule Anatomy 0.000 description 6
• 201000001119 neuropathy Diseases 0.000 description 6
• 230000007823 neuropathy Effects 0.000 description 6
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
• 150000004033 porphyrin derivatives Chemical class 0.000 description 6
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 6
• 239000011734 sodium Substances 0.000 description 6
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 6
• 201000004384 Alopecia Diseases 0.000 description 5
• 208000019901 Anxiety disease Diseases 0.000 description 5
• 208000020925 Bipolar disease Diseases 0.000 description 5
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 231100000360 alopecia Toxicity 0.000 description 5
• 230000036506 anxiety Effects 0.000 description 5
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
• ZUBTZRPXJLZWKF-UHFFFAOYSA-N chembl285541 Chemical class N1C2=CC=CC=C2C2=C1CC1NC2CC1 ZUBTZRPXJLZWKF-UHFFFAOYSA-N 0.000 description 5
• 108010017146 dopamine D2L receptor Proteins 0.000 description 5
• 125000002541 furyl group Chemical group 0.000 description 5
• 229960001340 histamine Drugs 0.000 description 5
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
• 230000002265 prevention Effects 0.000 description 5
• 230000001737 promoting effect Effects 0.000 description 5
• 125000000714 pyrimidinyl group Chemical group 0.000 description 5
• 230000008733 trauma Effects 0.000 description 5
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
• IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 4
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 4
• 125000001054 5 membered carbocyclic group Chemical group 0.000 description 4
• 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 4
• 125000004008 6 membered carbocyclic group Chemical group 0.000 description 4
• 125000001960 7 membered carbocyclic group Chemical group 0.000 description 4
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
• MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical class CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 4
• 206010012289 Dementia Diseases 0.000 description 4
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
• WGCNASOHLSPBMP-UHFFFAOYSA-N Glycolaldehyde Chemical compound OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
• 102000003834 Histamine H1 Receptors Human genes 0.000 description 4
• 108090000110 Histamine H1 Receptors Proteins 0.000 description 4
• 206010020751 Hypersensitivity Diseases 0.000 description 4
• 102000004108 Neurotransmitter Receptors Human genes 0.000 description 4
• 108090000590 Neurotransmitter Receptors Proteins 0.000 description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
• NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
• 208000027418 Wounds and injury Diseases 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 150000001350 alkyl halides Chemical class 0.000 description 4
• 150000001408 amides Chemical class 0.000 description 4
• 230000006399 behavior Effects 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 230000001055 chewing effect Effects 0.000 description 4
• 239000000460 chlorine Substances 0.000 description 4
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
• OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 4
• 208000030533 eye disease Diseases 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 229910052736 halogen Inorganic materials 0.000 description 4
• 150000002367 halogens Chemical class 0.000 description 4
• 125000002883 imidazolyl group Chemical group 0.000 description 4
• 230000001965 increasing effect Effects 0.000 description 4
• 239000000543 intermediate Substances 0.000 description 4
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
• JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 4
• 230000013016 learning Effects 0.000 description 4
• UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
• 230000010807 negative regulation of binding Effects 0.000 description 4
• 230000003955 neuronal function Effects 0.000 description 4
• 235000018102 proteins Nutrition 0.000 description 4
• 102000004169 proteins and genes Human genes 0.000 description 4
• BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
• 125000000168 pyrrolyl group Chemical group 0.000 description 4
• 230000001953 sensory effect Effects 0.000 description 4
• 230000002295 serotoninergic effect Effects 0.000 description 4
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 4
• NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 4
• 125000001544 thienyl group Chemical group 0.000 description 4
• 238000004809 thin layer chromatography Methods 0.000 description 4
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
• GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
• QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
• XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 3
• WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 3
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
• 229940116892 5 Hydroxytryptamine 2B receptor antagonist Drugs 0.000 description 3
• 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 3
• 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 3
• 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 3
• 102100024956 5-hydroxytryptamine receptor 2B Human genes 0.000 description 3
• 101710138092 5-hydroxytryptamine receptor 2B Proteins 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
• 108010011485 Aspartame Proteins 0.000 description 3
• 208000036640 Asperger disease Diseases 0.000 description 3
• 201000006062 Asperger syndrome Diseases 0.000 description 3
• 208000002177 Cataract Diseases 0.000 description 3
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
• 206010010904 Convulsion Diseases 0.000 description 3
• 208000004262 Food Hypersensitivity Diseases 0.000 description 3
• 229930091371 Fructose Natural products 0.000 description 3
• 239000005715 Fructose Substances 0.000 description 3
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
• 239000005913 Maltodextrin Substances 0.000 description 3
• 229920002774 Maltodextrin Polymers 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 102000006386 Myelin Proteins Human genes 0.000 description 3
• 108010083674 Myelin Proteins Proteins 0.000 description 3
• 108010025020 Nerve Growth Factor Proteins 0.000 description 3
• 208000028389 Nerve injury Diseases 0.000 description 3
• 206010044565 Tremor Diseases 0.000 description 3
• PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 3
• 206010064930 age-related macular degeneration Diseases 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 3
• 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 3
• 239000000739 antihistaminic agent Substances 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
• 239000000605 aspartame Substances 0.000 description 3
• 235000010357 aspartame Nutrition 0.000 description 3
• 229960003438 aspartame Drugs 0.000 description 3
• 210000003050 axon Anatomy 0.000 description 3
• 230000003542 behavioural effect Effects 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 230000003197 catalytic effect Effects 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 229910052801 chlorine Inorganic materials 0.000 description 3
• 230000019771 cognition Effects 0.000 description 3
• 238000004440 column chromatography Methods 0.000 description 3
• 229940125773 compound 10 Drugs 0.000 description 3
• 229940125797 compound 12 Drugs 0.000 description 3
• 229940126214 compound 3 Drugs 0.000 description 3
• 238000013270 controlled release Methods 0.000 description 3
• 239000013078 crystal Substances 0.000 description 3
• 238000002425 crystallisation Methods 0.000 description 3
• 230000008025 crystallization Effects 0.000 description 3
• 230000006866 deterioration Effects 0.000 description 3
• 239000008121 dextrose Substances 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 229960003638 dopamine Drugs 0.000 description 3
• 210000005064 dopaminergic neuron Anatomy 0.000 description 3
• 239000000835 fiber Substances 0.000 description 3
• 229910052731 fluorine Inorganic materials 0.000 description 3
• 239000011737 fluorine Substances 0.000 description 3
• 235000020932 food allergy Nutrition 0.000 description 3
• 125000005842 heteroatom Chemical group 0.000 description 3
• 239000001257 hydrogen Substances 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
• 201000010901 lateral sclerosis Diseases 0.000 description 3
• 239000010410 layer Substances 0.000 description 3
• 230000033001 locomotion Effects 0.000 description 3
• 229940035034 maltodextrin Drugs 0.000 description 3
• 210000003470 mitochondria Anatomy 0.000 description 3
• 210000005012 myelin Anatomy 0.000 description 3
• BQIGMBPWIKZNQY-UHFFFAOYSA-N n-aminothiohydroxylamine Chemical class NNS BQIGMBPWIKZNQY-UHFFFAOYSA-N 0.000 description 3
• 230000008764 nerve damage Effects 0.000 description 3
• 210000000653 nervous system Anatomy 0.000 description 3
• 210000002241 neurite Anatomy 0.000 description 3
• 230000000926 neurological effect Effects 0.000 description 3
• 229960002748 norepinephrine Drugs 0.000 description 3
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
• 150000007530 organic bases Chemical class 0.000 description 3
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 230000001681 protective effect Effects 0.000 description 3
• 208000020016 psychiatric disease Diseases 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 150000003254 radicals Chemical class 0.000 description 3
• 238000007634 remodeling Methods 0.000 description 3
• 230000035807 sensation Effects 0.000 description 3
• 229910000104 sodium hydride Inorganic materials 0.000 description 3
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• 230000009747 swallowing Effects 0.000 description 3
• 230000004580 weight loss Effects 0.000 description 3
• 210000004885 white matter Anatomy 0.000 description 3
• NNWUEBIEOFQMSS-UHFFFAOYSA-N (+)-(S)-2-methylpiperidine Natural products CC1CCCCN1 NNWUEBIEOFQMSS-UHFFFAOYSA-N 0.000 description 2
• NNWUEBIEOFQMSS-LURJTMIESA-N (2s)-2-methylpiperidine Chemical compound C[C@H]1CCCCN1 NNWUEBIEOFQMSS-LURJTMIESA-N 0.000 description 2
• XAMBIJWZVIZZOG-UHFFFAOYSA-N (4-methylphenyl)hydrazine Chemical compound CC1=CC=C(NN)C=C1 XAMBIJWZVIZZOG-UHFFFAOYSA-N 0.000 description 2
• MUZSTDFLNXNYKR-UHFFFAOYSA-N 1-(4-methylphenyl)-1-(1-phenylethyl)hydrazine Chemical compound C1(=CC=CC=C1)C(C)N(N)C1=CC=C(C=C1)C MUZSTDFLNXNYKR-UHFFFAOYSA-N 0.000 description 2
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
• UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
• LBUPWCHXRSTTNO-UHFFFAOYSA-N 2,2-dimethylpiperidine Chemical compound CC1(C)CCCCN1 LBUPWCHXRSTTNO-UHFFFAOYSA-N 0.000 description 2
• IFNWESYYDINUHV-UHFFFAOYSA-N 2,6-dimethylpiperazine Chemical compound CC1CNCC(C)N1 IFNWESYYDINUHV-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
• 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
• 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 2
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
• UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 2
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
• 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 2
• 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 2
• 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 description 2
• 102100036666 Alpha-2B adrenergic receptor Human genes 0.000 description 2
• 208000000044 Amnesia Diseases 0.000 description 2
• 208000037259 Amyloid Plaque Diseases 0.000 description 2
• 201000004569 Blindness Diseases 0.000 description 2
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 244000025254 Cannabis sativa Species 0.000 description 2
• 208000028698 Cognitive impairment Diseases 0.000 description 2
• 206010012239 Delusion Diseases 0.000 description 2
• 208000012239 Developmental disease Diseases 0.000 description 2
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• 108091006027 G proteins Proteins 0.000 description 2
• 102000030782 GTP binding Human genes 0.000 description 2
• 108091000058 GTP-Binding Proteins 0.000 description 2
• 229920002148 Gellan gum Polymers 0.000 description 2
• 208000004547 Hallucinations Diseases 0.000 description 2
• 102000003710 Histamine H2 Receptors Human genes 0.000 description 2
• 108090000050 Histamine H2 Receptors Proteins 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 206010028372 Muscular weakness Diseases 0.000 description 2
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
• HPDBWJFPVTXIJU-UHFFFAOYSA-N N1CCNCC1.C(C)NN Chemical compound N1CCNCC1.C(C)NN HPDBWJFPVTXIJU-UHFFFAOYSA-N 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 102000015336 Nerve Growth Factor Human genes 0.000 description 2
• 206010034719 Personality change Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 206010036105 Polyneuropathy Diseases 0.000 description 2
• 208000008348 Post-Concussion Syndrome Diseases 0.000 description 2
• 108010050254 Presenilins Proteins 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 206010037779 Radiculopathy Diseases 0.000 description 2
• 208000006289 Rett Syndrome Diseases 0.000 description 2
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
• 206010047571 Visual impairment Diseases 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 230000000996 additive effect Effects 0.000 description 2
• 125000003158 alcohol group Chemical group 0.000 description 2
• 125000002877 alkyl aryl group Chemical group 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
• 230000001387 anti-histamine Effects 0.000 description 2
• 229940124623 antihistamine drug Drugs 0.000 description 2
• 101150031224 app gene Proteins 0.000 description 2
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 230000003935 attention Effects 0.000 description 2
• 208000029560 autism spectrum disease Diseases 0.000 description 2
• 210000004227 basal ganglia Anatomy 0.000 description 2
• 208000013404 behavioral symptom Diseases 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 208000029028 brain injury Diseases 0.000 description 2
• 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• 125000001246 bromo group Chemical group Br* 0.000 description 2
• ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
• 229910000019 calcium carbonate Inorganic materials 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 125000005243 carbonyl alkyl group Chemical group 0.000 description 2
• 150000001733 carboxylic acid esters Chemical class 0.000 description 2
• 235000010418 carrageenan Nutrition 0.000 description 2
• 239000000679 carrageenan Substances 0.000 description 2
• 229920001525 carrageenan Polymers 0.000 description 2
• 229940113118 carrageenan Drugs 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 230000002490 cerebral effect Effects 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 238000004891 communication Methods 0.000 description 2
• 230000006854 communication Effects 0.000 description 2
• 230000009850 completed effect Effects 0.000 description 2
• 229940125782 compound 2 Drugs 0.000 description 2
• 229940125898 compound 5 Drugs 0.000 description 2
• 238000007906 compression Methods 0.000 description 2
• 230000006835 compression Effects 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 230000007850 degeneration Effects 0.000 description 2
• 230000003412 degenerative effect Effects 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 231100000868 delusion Toxicity 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 238000005538 encapsulation Methods 0.000 description 2
• DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 2
• GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 238000005227 gel permeation chromatography Methods 0.000 description 2
• 235000010492 gellan gum Nutrition 0.000 description 2
• 239000000216 gellan gum Substances 0.000 description 2
• 239000003349 gelling agent Substances 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
• 239000005457 ice water Substances 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 239000012535 impurity Substances 0.000 description 2
• 239000005414 inactive ingredient Substances 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 230000002427 irreversible effect Effects 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 230000008449 language Effects 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000006386 memory function Effects 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 230000004065 mitochondrial dysfunction Effects 0.000 description 2
• 230000004898 mitochondrial function Effects 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 150000004682 monohydrates Chemical class 0.000 description 2
• 201000005518 mononeuropathy Diseases 0.000 description 2
• 125000002757 morpholinyl group Chemical group 0.000 description 2
• 208000005264 motor neuron disease Diseases 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 229940053128 nerve growth factor Drugs 0.000 description 2
• 238000003522 neurite outgrowth assay Methods 0.000 description 2
• 210000000715 neuromuscular junction Anatomy 0.000 description 2
• 230000005015 neuronal process Effects 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• 108020004707 nucleic acids Proteins 0.000 description 2
• 150000007523 nucleic acids Chemical class 0.000 description 2
• 102000039446 nucleic acids Human genes 0.000 description 2
• 210000004248 oligodendroglia Anatomy 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000006408 oxalic acid Nutrition 0.000 description 2
• 229910052760 oxygen Chemical group 0.000 description 2
• 239000001301 oxygen Chemical group 0.000 description 2
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• 125000003884 phenylalkyl group Chemical group 0.000 description 2
• 230000007824 polyneuropathy Effects 0.000 description 2
• 150000004032 porphyrins Chemical class 0.000 description 2
• 201000008752 progressive muscular atrophy Diseases 0.000 description 2
• 201000003004 ptosis Diseases 0.000 description 2
• 238000001953 recrystallisation Methods 0.000 description 2
• 230000003989 repetitive behavior Effects 0.000 description 2
• 208000013406 repetitive behavior Diseases 0.000 description 2
• 230000029058 respiratory gaseous exchange Effects 0.000 description 2
• 210000001525 retina Anatomy 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 229930195734 saturated hydrocarbon Natural products 0.000 description 2
• 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 2
• 230000001568 sexual effect Effects 0.000 description 2
• 230000008454 sleep-wake cycle Effects 0.000 description 2
• 230000003997 social interaction Effects 0.000 description 2
• 239000012312 sodium hydride Substances 0.000 description 2
• 239000008109 sodium starch glycolate Substances 0.000 description 2
• 229920003109 sodium starch glycolate Polymers 0.000 description 2
• 229940079832 sodium starch glycolate Drugs 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 210000000273 spinal nerve root Anatomy 0.000 description 2
• 125000003003 spiro group Chemical group 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 239000011593 sulfur Chemical group 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 230000000946 synaptic effect Effects 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• 238000012549 training Methods 0.000 description 2
• 208000029257 vision disease Diseases 0.000 description 2
• 230000004393 visual impairment Effects 0.000 description 2
• 230000004584 weight gain Effects 0.000 description 2
• 235000019786 weight gain Nutrition 0.000 description 2
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
• AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
• SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
• ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
• WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
• IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
• FDQGNUSTPULKCR-UHFFFAOYSA-N (4-iodophenyl)phosphane Chemical compound PC1=CC=C(I)C=C1 FDQGNUSTPULKCR-UHFFFAOYSA-N 0.000 description 1
• 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
• DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 1
• VLKFFPJRVJKGOA-UHFFFAOYSA-N 1-(4-methylphenyl)-1-phenylhydrazine Chemical compound C1=CC(C)=CC=C1N(N)C1=CC=CC=C1 VLKFFPJRVJKGOA-UHFFFAOYSA-N 0.000 description 1
• ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
• WHKWMTXTYKVFLK-UHFFFAOYSA-N 1-propan-2-ylpiperazine Chemical compound CC(C)N1CCNCC1 WHKWMTXTYKVFLK-UHFFFAOYSA-N 0.000 description 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
• YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
• TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• NSWLMOHUXYULKL-UHFFFAOYSA-N 2-chloro-1-piperidin-1-ylethanone Chemical compound ClCC(=O)N1CCCCC1 NSWLMOHUXYULKL-UHFFFAOYSA-N 0.000 description 1
• MNNZINNZIQVULG-UHFFFAOYSA-N 2-chloroethylbenzene Chemical compound ClCCC1=CC=CC=C1 MNNZINNZIQVULG-UHFFFAOYSA-N 0.000 description 1
• QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
• 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
• 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 1
• 229940124801 5-HT6 antagonist Drugs 0.000 description 1
• OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
• 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
• 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
• HUGYQXFQBHWMQD-UHFFFAOYSA-N 8-methyl-8-azabicyclo[3.2.1]octan-3-one;hydrochloride Chemical compound Cl.C1C(=O)CC2CCC1N2C HUGYQXFQBHWMQD-UHFFFAOYSA-N 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• 206010001497 Agitation Diseases 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 206010002942 Apathy Diseases 0.000 description 1
• 108010060159 Apolipoprotein E4 Proteins 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 208000025978 Athletic injury Diseases 0.000 description 1
• 208000025165 Autoerythrocyte sensitization syndrome Diseases 0.000 description 1
• 206010061666 Autonomic neuropathy Diseases 0.000 description 1
• 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 206010006100 Bradykinesia Diseases 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• ZIYYRVOJQRCRNF-UHFFFAOYSA-N C12=CC=CC=C2N(C(O)C)C2=C1C(N1)CCC1C2 Chemical class C12=CC=CC=C2N(C(O)C)C2=C1C(N1)CCC1C2 ZIYYRVOJQRCRNF-UHFFFAOYSA-N 0.000 description 1
• KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
• 241000824799 Canis lupus dingo Species 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
• 108010009685 Cholinergic Receptors Proteins 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 206010009696 Clumsiness Diseases 0.000 description 1
• 208000006992 Color Vision Defects Diseases 0.000 description 1
• 229940126657 Compound 17 Drugs 0.000 description 1
• 206010010305 Confusional state Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
• 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• 101710112752 Cytotoxin Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012305 Demyelination Diseases 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 208000003164 Diplopia Diseases 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
• 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
• 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
• 201000001353 Doyne honeycomb retinal dystrophy Diseases 0.000 description 1
• 208000012661 Dyskinesia Diseases 0.000 description 1
• 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 description 1
• 208000032274 Encephalopathy Diseases 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 206010015995 Eyelid ptosis Diseases 0.000 description 1
• 208000013171 Fahr disease Diseases 0.000 description 1
• 208000037312 Familial drusen Diseases 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 229930195212 Fischerindole Natural products 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 101150104779 HTR2A gene Proteins 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
• 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
• 208000007514 Herpes zoster Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 102100032499 Histamine H2 receptor Human genes 0.000 description 1
• 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
• 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 description 1
• 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
• 101001016827 Homo sapiens Histamine H2 receptor Proteins 0.000 description 1
• 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
• 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
• 101001109698 Homo sapiens Nuclear receptor subfamily 4 group A member 2 Proteins 0.000 description 1
• 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
• 101150013372 Htr2c gene Proteins 0.000 description 1
• 241000257303 Hymenoptera Species 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 208000006083 Hypokinesia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000009032 Imidazoline Receptors Human genes 0.000 description 1
• 108010049134 Imidazoline Receptors Proteins 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 208000032578 Inherited retinal disease Diseases 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
• 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
• 206010024264 Lethargy Diseases 0.000 description 1
• 208000009829 Lewy Body Disease Diseases 0.000 description 1
• 201000002832 Lewy body dementia Diseases 0.000 description 1
• 241000186781 Listeria Species 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 208000035719 Maculopathy Diseases 0.000 description 1
• 208000002720 Malnutrition Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 1
• 208000012583 Menkes disease Diseases 0.000 description 1
• 208000027382 Mental deterioration Diseases 0.000 description 1
• 206010027374 Mental impairment Diseases 0.000 description 1
• 102100021118 Microtubule-associated protein 2 Human genes 0.000 description 1
• 206010027910 Mononeuritis Diseases 0.000 description 1
• 206010027951 Mood swings Diseases 0.000 description 1
• 208000010428 Muscle Weakness Diseases 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• 206010028347 Muscle twitching Diseases 0.000 description 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
• OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
• 102000007072 Nerve Growth Factors Human genes 0.000 description 1
• 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
• 102000008763 Neurofilament Proteins Human genes 0.000 description 1
• 108010088373 Neurofilament Proteins Proteins 0.000 description 1
• 206010060860 Neurological symptom Diseases 0.000 description 1
• 206010029350 Neurotoxicity Diseases 0.000 description 1
• 208000001140 Night Blindness Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
• 208000016113 North Carolina macular dystrophy Diseases 0.000 description 1
• 102100022676 Nuclear receptor subfamily 4 group A member 2 Human genes 0.000 description 1
• 208000013661 Oguchi disease Diseases 0.000 description 1
• 206010061323 Optic neuropathy Diseases 0.000 description 1
• 206010053159 Organ failure Diseases 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000028361 Penetrating Head injury Diseases 0.000 description 1
• 102000004590 Peripherins Human genes 0.000 description 1
• 108010003081 Peripherins Proteins 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
• 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 208000032430 Retinal dystrophy Diseases 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 206010039897 Sedation Diseases 0.000 description 1
• 206010040030 Sensory loss Diseases 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 208000022758 Sorsby fundus dystrophy Diseases 0.000 description 1
• 201000010829 Spina bifida Diseases 0.000 description 1
• 208000006097 Spinal Dysraphism Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000027073 Stargardt disease Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 102000019355 Synuclein Human genes 0.000 description 1
• 108050006783 Synuclein Proteins 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 206010043431 Thinking abnormal Diseases 0.000 description 1
• 206010044221 Toxic encephalopathy Diseases 0.000 description 1
• 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 102000004243 Tubulin Human genes 0.000 description 1
• 108090000704 Tubulin Proteins 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 208000014769 Usher Syndromes Diseases 0.000 description 1
• 241000256856 Vespidae Species 0.000 description 1
• 208000021017 Weight Gain Diseases 0.000 description 1
• 208000018839 Wilson disease Diseases 0.000 description 1
• 238000002441 X-ray diffraction Methods 0.000 description 1
• LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
• QKDWTVSZNMBHKZ-UHFFFAOYSA-L [K+].[K+].[O-]C([O-])=O.CC1=CC=CC=C1 Chemical compound [K+].[K+].[O-]C([O-])=O.CC1=CC=CC=C1 QKDWTVSZNMBHKZ-UHFFFAOYSA-L 0.000 description 1
• WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 235000011054 acetic acid Nutrition 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• FXAGBTBXSJBNMD-UHFFFAOYSA-N acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FXAGBTBXSJBNMD-UHFFFAOYSA-N 0.000 description 1
• 102000034337 acetylcholine receptors Human genes 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 208000037919 acquired disease Diseases 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 239000000048 adrenergic agonist Substances 0.000 description 1
• 239000000674 adrenergic antagonist Substances 0.000 description 1
• 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 229910001413 alkali metal ion Inorganic materials 0.000 description 1
• 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
• 125000003302 alkenyloxy group Chemical group 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 125000005133 alkynyloxy group Chemical group 0.000 description 1
• 239000013566 allergen Substances 0.000 description 1
• 208000030961 allergic reaction Diseases 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 239000004855 amber Substances 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 125000005577 anthracene group Chemical group 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 230000004596 appetite loss Effects 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 201000002922 basal ganglia calcification Diseases 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 238000010009 beating Methods 0.000 description 1
• 230000006736 behavioral deficit Effects 0.000 description 1
• 231100000871 behavioral problem Toxicity 0.000 description 1
• 150000001555 benzenes Chemical class 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 208000016791 bilateral striopallidodentate calcinosis Diseases 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 239000003150 biochemical marker Substances 0.000 description 1
• SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
• 238000004820 blood count Methods 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 210000004958 brain cell Anatomy 0.000 description 1
• 210000001775 bruch membrane Anatomy 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 229960003563 calcium carbonate Drugs 0.000 description 1
• AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
• 239000000920 calcium hydroxide Substances 0.000 description 1
• 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
• 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
• 229960001631 carbomer Drugs 0.000 description 1
• 229910021386 carbon form Inorganic materials 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 230000004637 cellular stress Effects 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 210000001638 cerebellum Anatomy 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
• 210000002932 cholinergic neuron Anatomy 0.000 description 1
• 208000012601 choreatic disease Diseases 0.000 description 1
• 210000003161 choroid Anatomy 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 230000007278 cognition impairment Effects 0.000 description 1
• 230000003930 cognitive ability Effects 0.000 description 1
• 230000006999 cognitive decline Effects 0.000 description 1
• 231100000876 cognitive deterioration Toxicity 0.000 description 1
• 230000037411 cognitive enhancing Effects 0.000 description 1
• 230000036992 cognitive tasks Effects 0.000 description 1
• 201000007254 color blindness Diseases 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 229940126543 compound 14 Drugs 0.000 description 1
• 229940125758 compound 15 Drugs 0.000 description 1
• 229940126142 compound 16 Drugs 0.000 description 1
• 229940125810 compound 20 Drugs 0.000 description 1
• 229940126086 compound 21 Drugs 0.000 description 1
• 229940126208 compound 22 Drugs 0.000 description 1
• 229940125833 compound 23 Drugs 0.000 description 1
• 229940125961 compound 24 Drugs 0.000 description 1
• 229940125846 compound 25 Drugs 0.000 description 1
• 229940125851 compound 27 Drugs 0.000 description 1
• 231100000867 compulsive behavior Toxicity 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 229910000365 copper sulfate Inorganic materials 0.000 description 1
• ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
• 210000003618 cortical neuron Anatomy 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 229960001681 croscarmellose sodium Drugs 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 239000013058 crude material Substances 0.000 description 1
• 238000011461 current therapy Methods 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• QQEWMMRFXYVLQU-UHFFFAOYSA-N decylhydrazine Chemical class CCCCCCCCCCNN QQEWMMRFXYVLQU-UHFFFAOYSA-N 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 210000001787 dendrite Anatomy 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 125000004982 dihaloalkyl group Chemical group 0.000 description 1
• 238000007907 direct compression Methods 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
• 230000003291 dopaminomimetic effect Effects 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 230000002996 emotional effect Effects 0.000 description 1
• 210000003372 endocrine gland Anatomy 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 239000003256 environmental substance Substances 0.000 description 1
• MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000004438 eyesight Effects 0.000 description 1
• 230000008921 facial expression Effects 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 201000006321 fundus dystrophy Diseases 0.000 description 1
• 230000035784 germination Effects 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000003979 granulating agent Substances 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 210000004884 grey matter Anatomy 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 230000005802 health problem Effects 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
• 210000004295 hippocampal neuron Anatomy 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 235000012907 honey Nutrition 0.000 description 1
• 150000002429 hydrazines Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 230000003301 hydrolyzing effect Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 150000002475 indoles Chemical class 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 230000010365 information processing Effects 0.000 description 1
• 238000002329 infrared spectrum Methods 0.000 description 1
• 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 239000013067 intermediate product Substances 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
• PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 150000003951 lactams Chemical class 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 210000003715 limbic system Anatomy 0.000 description 1
• 235000021266 loss of appetite Nutrition 0.000 description 1
• 208000019017 loss of appetite Diseases 0.000 description 1
• 231100000863 loss of memory Toxicity 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 230000001071 malnutrition Effects 0.000 description 1
• 235000000824 malnutrition Nutrition 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000006984 memory degeneration Effects 0.000 description 1
• 208000023060 memory loss Diseases 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 230000003924 mental process Effects 0.000 description 1
• YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
• 229960000582 mepyramine Drugs 0.000 description 1
• 210000001259 mesencephalon Anatomy 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 230000007625 mitochondrial abnormality Effects 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 208000013734 mononeuritis simplex Diseases 0.000 description 1
• 230000020763 muscle atrophy Effects 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 201000000585 muscular atrophy Diseases 0.000 description 1
• 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 210000003061 neural cell Anatomy 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 238000002610 neuroimaging Methods 0.000 description 1
• 238000010984 neurological examination Methods 0.000 description 1
• 230000002232 neuromuscular Effects 0.000 description 1
• 230000006764 neuronal dysfunction Effects 0.000 description 1
• 230000007171 neuropathology Effects 0.000 description 1
• 239000004090 neuroprotective agent Substances 0.000 description 1
• 231100000228 neurotoxicity Toxicity 0.000 description 1
• 230000007135 neurotoxicity Effects 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 150000002825 nitriles Chemical class 0.000 description 1
• 231100000862 numbness Toxicity 0.000 description 1
• 208000015380 nutritional deficiency disease Diseases 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 201000001909 oculomotor nerve paralysis Diseases 0.000 description 1
• 208000020911 optic nerve disease Diseases 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 150000003891 oxalate salts Chemical class 0.000 description 1
• 150000002924 oxiranes Chemical class 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 208000027753 pain disease Diseases 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 102000045222 parkin Human genes 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000000578 peripheral nerve Anatomy 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 210000005047 peripherin Anatomy 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229940127557 pharmaceutical product Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 108091008695 photoreceptors Proteins 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
• 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000001144 postural effect Effects 0.000 description 1
• 229940069328 povidone Drugs 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 210000002243 primary neuron Anatomy 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 201000002241 progressive bulbar palsy Diseases 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 239000003223 protective agent Substances 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000002294 pubertal effect Effects 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 201000004193 respiratory failure Diseases 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 210000004116 schwann cell Anatomy 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 230000036280 sedation Effects 0.000 description 1
• 210000001044 sensory neuron Anatomy 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 239000000952 serotonin receptor agonist Substances 0.000 description 1
• 229940121356 serotonin receptor antagonist Drugs 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 230000006403 short-term memory Effects 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 229920002379 silicone rubber Polymers 0.000 description 1
• 239000004945 silicone rubber Substances 0.000 description 1
• 238000011125 single therapy Methods 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 235000015424 sodium Nutrition 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 208000027765 speech disease Diseases 0.000 description 1
• 208000002320 spinal muscular atrophy Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 229940032147 starch Drugs 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000012258 stirred mixture Substances 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
• 125000004964 sulfoalkyl group Chemical group 0.000 description 1
• RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
• 125000004354 sulfur functional group Chemical group 0.000 description 1
• 230000002889 sympathetic effect Effects 0.000 description 1
• 230000007470 synaptic degeneration Effects 0.000 description 1
• 230000005062 synaptic transmission Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• RLUJQBLWUQZMDG-UHFFFAOYSA-N toluene;hydrochloride Chemical compound Cl.CC1=CC=CC=C1 RLUJQBLWUQZMDG-UHFFFAOYSA-N 0.000 description 1
• 238000003325 tomography Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
• 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
• 238000002562 urinalysis Methods 0.000 description 1
• 239000002435 venom Substances 0.000 description 1
• 210000001048 venom Anatomy 0.000 description 1
• 231100000611 venom Toxicity 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 230000004304 visual acuity Effects 0.000 description 1
• 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
• 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1